vs

Side-by-side financial comparison of PROCEPT BioRobotics Corp (PRCT) and TXO Partners, L.P. (TXO). Click either name above to swap in a different company.

TXO Partners, L.P. is the larger business by last-quarter revenue ($103.7M vs $83.1M, roughly 1.2× PROCEPT BioRobotics Corp). TXO Partners, L.P. runs the higher net margin — -27.2% vs -38.1%, a 10.8% gap on every dollar of revenue. On growth, PROCEPT BioRobotics Corp posted the faster year-over-year revenue change (20.2% vs 14.5%). Over the past eight quarters, PROCEPT BioRobotics Corp's revenue compounded faster (24.8% CAGR vs 23.1%).

PROCEPT BioRobotics Corp is a medical tech firm developing and commercializing robotic surgical solutions for urological care. Its flagship AquaBeam system provides image-guided minimally invasive therapy for benign prostatic hyperplasia, serving providers and patients across North America, Europe and global markets.

TXO Partners, L.P. is a U.S.-based energy sector master limited partnership. It acquires, develops and manages oil and natural gas assets across key North American production basins, with operations covering upstream exploration, production and midstream transportation, serving industrial, utility and wholesale energy clients.

PRCT vs TXO — Head-to-Head

Bigger by revenue
TXO
TXO
1.2× larger
TXO
$103.7M
$83.1M
PRCT
Growing faster (revenue YoY)
PRCT
PRCT
+5.7% gap
PRCT
20.2%
14.5%
TXO
Higher net margin
TXO
TXO
10.8% more per $
TXO
-27.2%
-38.1%
PRCT
Faster 2-yr revenue CAGR
PRCT
PRCT
Annualised
PRCT
24.8%
23.1%
TXO

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
PRCT
PRCT
TXO
TXO
Revenue
$83.1M
$103.7M
Net Profit
$-31.6M
$-28.3M
Gross Margin
64.9%
Operating Margin
-4.1%
-26.1%
Net Margin
-38.1%
-27.2%
Revenue YoY
20.2%
14.5%
Net Profit YoY
-27.9%
-376.5%
EPS (diluted)
$-0.56
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PRCT
PRCT
TXO
TXO
Q1 26
$83.1M
Q4 25
$76.4M
$103.7M
Q3 25
$83.3M
$90.6M
Q2 25
$79.2M
$75.0M
Q1 25
$69.2M
$93.8M
Q4 24
$68.2M
$90.6M
Q3 24
$58.4M
$69.3M
Q2 24
$53.4M
$57.0M
Net Profit
PRCT
PRCT
TXO
TXO
Q1 26
$-31.6M
Q4 25
$-29.8M
$-28.3M
Q3 25
$-21.4M
$4.4M
Q2 25
$-19.6M
$-135.0K
Q1 25
$-24.7M
$2.4M
Q4 24
$-18.9M
$10.2M
Q3 24
$-21.0M
$203.0K
Q2 24
$-25.6M
$2.8M
Gross Margin
PRCT
PRCT
TXO
TXO
Q1 26
64.9%
Q4 25
60.6%
Q3 25
64.8%
Q2 25
65.4%
Q1 25
63.9%
Q4 24
64.0%
Q3 24
63.2%
Q2 24
59.0%
Operating Margin
PRCT
PRCT
TXO
TXO
Q1 26
-4.1%
Q4 25
-40.6%
-26.1%
Q3 25
-27.8%
4.2%
Q2 25
-28.0%
-5.0%
Q1 25
-39.7%
-3.8%
Q4 24
-28.9%
6.1%
Q3 24
-38.4%
-7.2%
Q2 24
-50.3%
-17.7%
Net Margin
PRCT
PRCT
TXO
TXO
Q1 26
-38.1%
Q4 25
-39.1%
-27.2%
Q3 25
-25.7%
4.8%
Q2 25
-24.7%
-0.2%
Q1 25
-35.8%
2.6%
Q4 24
-27.6%
11.3%
Q3 24
-35.9%
0.3%
Q2 24
-48.0%
4.9%
EPS (diluted)
PRCT
PRCT
TXO
TXO
Q1 26
$-0.56
Q4 25
$-0.54
$-0.57
Q3 25
$-0.38
$0.08
Q2 25
$-0.35
$0.00
Q1 25
$-0.45
$0.06
Q4 24
$-0.34
$0.22
Q3 24
$-0.40
$0.01
Q2 24
$-0.50
$0.09

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PRCT
PRCT
TXO
TXO
Cash + ST InvestmentsLiquidity on hand
$245.6M
$9.4M
Total DebtLower is stronger
$51.7M
$291.1M
Stockholders' EquityBook value
$347.7M
Total Assets
$487.1M
$1.4B
Debt / EquityLower = less leverage
0.15×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PRCT
PRCT
TXO
TXO
Q1 26
$245.6M
Q4 25
$286.5M
$9.4M
Q3 25
$294.3M
$5.3M
Q2 25
$302.7M
$8.0M
Q1 25
$316.2M
$10.8M
Q4 24
$333.7M
$7.3M
Q3 24
$196.8M
$3.8M
Q2 24
$214.1M
$76.0M
Total Debt
PRCT
PRCT
TXO
TXO
Q1 26
$51.7M
Q4 25
$51.6M
$291.1M
Q3 25
$51.6M
$271.1M
Q2 25
$51.5M
$19.1M
Q1 25
$51.5M
$162.1M
Q4 24
$51.5M
$157.1M
Q3 24
$51.4M
$155.1M
Q2 24
$51.4M
$7.1M
Stockholders' Equity
PRCT
PRCT
TXO
TXO
Q1 26
$347.7M
Q4 25
$365.9M
Q3 25
$380.3M
Q2 25
$385.8M
Q1 25
$389.2M
Q4 24
$402.2M
Q3 24
$241.2M
Q2 24
$251.8M
Total Assets
PRCT
PRCT
TXO
TXO
Q1 26
$487.1M
Q4 25
$508.1M
$1.4B
Q3 25
$511.5M
$1.4B
Q2 25
$513.1M
$1.0B
Q1 25
$519.4M
$1.0B
Q4 24
$534.0M
$1.0B
Q3 24
$374.1M
$1.0B
Q2 24
$374.4M
$774.5M
Debt / Equity
PRCT
PRCT
TXO
TXO
Q1 26
0.15×
Q4 25
0.14×
Q3 25
0.14×
Q2 25
0.13×
Q1 25
0.13×
Q4 24
0.13×
Q3 24
0.21×
Q2 24
0.20×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PRCT
PRCT
TXO
TXO
Operating Cash FlowLast quarter
$32.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PRCT
PRCT
TXO
TXO
Q1 26
Q4 25
$-10.3M
$32.5M
Q3 25
$-6.6M
$28.3M
Q2 25
$-15.0M
$26.9M
Q1 25
$-17.0M
$30.6M
Q4 24
$-32.4M
$40.5M
Q3 24
$-18.8M
$20.7M
Q2 24
$-15.7M
$22.9M
Free Cash Flow
PRCT
PRCT
TXO
TXO
Q1 26
Q4 25
$-12.2M
Q3 25
$-9.5M
Q2 25
$-17.8M
Q1 25
$-18.8M
Q4 24
$-33.6M
Q3 24
$-19.0M
Q2 24
$-16.8M
FCF Margin
PRCT
PRCT
TXO
TXO
Q1 26
Q4 25
-15.9%
Q3 25
-11.4%
Q2 25
-22.5%
Q1 25
-27.2%
Q4 24
-49.2%
Q3 24
-32.6%
Q2 24
-31.4%
Capex Intensity
PRCT
PRCT
TXO
TXO
Q1 26
Q4 25
2.4%
Q3 25
3.4%
Q2 25
3.5%
Q1 25
2.7%
Q4 24
1.7%
Q3 24
0.4%
Q2 24
2.0%
Cash Conversion
PRCT
PRCT
TXO
TXO
Q1 26
Q4 25
Q3 25
6.50×
Q2 25
Q1 25
12.67×
Q4 24
3.96×
Q3 24
102.02×
Q2 24
8.15×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PRCT
PRCT

Handpieces and other consumables$43.0M52%
System sales and rentals$23.4M28%
Other$11.1M13%
Service$5.6M7%

TXO
TXO

Oil And Condensate$92.8M89%
Natural Gas Liquids Reserves$8.2M8%
Other$2.8M3%

Related Comparisons